Compare GNL & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNL | OCUL |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | 56 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | N/A | 2014 |
| Metric | GNL | OCUL |
|---|---|---|
| Price | $9.29 | $8.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $9.67 | ★ $23.56 |
| AVG Volume (30 Days) | 1.7M | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,990,000.00 |
| Revenue This Year | N/A | $7.93 |
| Revenue Next Year | $1.95 | $96.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.48 |
| 52 Week Low | $6.77 | $6.23 |
| 52 Week High | $10.04 | $16.44 |
| Indicator | GNL | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 33.07 |
| Support Level | $9.31 | $7.38 |
| Resistance Level | $9.72 | $9.93 |
| Average True Range (ATR) | 0.16 | 0.46 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 55.07 | 0.24 |
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operation, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution, Retail, and Office. The company derives maximum revenue from the Industrial and Distribution segment. The company geographically operates in the United States, the United Kingdom, Canada, and Europe.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.